



Title	Novel pathophysiological insight and treatment strategies for heart failure : lessons from mice and patients
Author(s)	Tsutsui, Hiroyuki
Citation	Circulation Journal, 68(12), 1095-1103 <a href="https://doi.org/10.1253/circj.68.1095">https://doi.org/10.1253/circj.68.1095</a>
Issue Date	2004-12
Doc URL	<a href="http://hdl.handle.net/2115/16986">http://hdl.handle.net/2115/16986</a>
Type	article (author version)
File Information	CJ68-12.pdf



[Instructions for use](#)

**SPECIAL ARTICLE for "Circulation Journal"**

**Novel Pathophysiological Insight and Treatment Strategies for Heart Failure  
~Lessons From Mice and Patients~**

Running head: Pathophysiology and treatment of heart failure

Hiroyuki Tsutsui, MD, PhD

Department of Cardiovascular Medicine, Graduate School of Medical Sciences,  
Kyushu University, Fukuoka 812-8582, Japan

Address for correspondence:

Hiroyuki Tsutsui, M.D., Ph.D.

Department of Cardiovascular Medicine,

Hokkaido University Graduate School of Medicine,

Kita-15, Nishi-7, Kita-ku,

Sapporo, 060-8638

Japan

Tel: +81-11-706-6970

Fax: +81-11-706-7874

E-mail: [htsutsui@med.hokudai.ac.jp](mailto:htsutsui@med.hokudai.ac.jp)

## **Abstract**

Our ultimate goal of heart failure (HF) treatment is to improve the prognosis of patients. Previous basic, clinical, and population sciences have advanced the modern treatment of HF. However, its efficacy is still limited especially in the “real world” patients. There are two approaches to solve this crucial issue. First is the further development of novel therapeutic strategies based on a novel insight into the pathophysiology of myocardial remodeling and failure. Second is the improvement of quality of care in routine clinical practice. Our basic approach is to develop the therapeutic strategy of myocardial remodeling by regulating mitochondrial oxidative stress. In the failing hearts, oxygen radicals are produced by the defects of mitochondrial electron transport. They cause mitochondrial DNA damage and functional decline, leading to the further production of oxygen radicals. Oxidative stress causes myocyte hypertrophy, apoptosis, and interstitial fibrosis by activating matrix metalloproteinases, all of which result in myocardial remodeling and failure. Therefore, mitochondrial oxidative stress and DNA damage are good therapeutic targets. Our clinical approach is to develop the effective strategies of HF management for the “real world” patients. Readmission due to the exacerbation is common in HF patients and further impairs the quality of life. Noncompliance to the treatment is the most common precipitating factor for readmission. Regular medical follow-up and social support are important components which should be included in the disease management program of HF patients. These basic and clinical approaches are needed to establish the novel and most effective treatment strategies for Japanese patients with HF.

**Key words:** Heart failure; Remodeling; Oxidative stress; Mitochondria; Mortality; Readmission

Congestive heart failure (HF) is a leading cause of morbidity and mortality in industrialized countries.<sup>1</sup> It is also a growing public health problem, mainly because of aging of the population and the increase in the prevalence of HF in the elderly. Previous basic, clinical, and population sciences have advanced the modern treatment of HF. However, its efficacy is still limited especially in the “real world” patients. There are two approaches to solve this crucial issue. First is the further development of therapeutic strategies based on a novel insight into the pathophysiology of myocardial remodeling and failure. Second is the improvement of quality of care in routine clinical practice.

### **Basic Approach:**

## **Novel Pathophysiological Insight and Treatment Strategies of Myocardial Remodeling By Regulating Oxidative Stress**

### **Mechanisms and Consequences of Oxidative Stress in HF**

Reactive oxygen species (ROS) such as superoxide anions ( $\cdot\text{O}_2^-$ ) and hydroxy radicals ( $\cdot\text{OH}$ ) cause the oxidation of membrane phospholipids, proteins, and DNAs<sup>2</sup> and have been implicated in a wide range of pathological conditions including ischemia-reperfusion injury, neurodegenerative diseases, and aging. Under physiological conditions, their toxic effects can be prevented by such scavenging enzymes as superoxide dismutase (SOD), glutathione peroxidase (GSHPx), and catalase as well as by other non-enzymatic antioxidants. However, when the production of ROS becomes excessive, oxidative stress might have a harmful effect on the functional and structural integrity of biological tissue. ROS cause contractile failure and structural damage in the myocardium. The importance of oxidative stress is increasingly emerging with respect to a pathophysiological mechanism of left ventricular (LV) remodeling and failure responsible for HF progression.

### *Increased ROS Production Within the Failing Myocardium*

Recent experimental and clinical investigations have suggested the generation of ROS to increase in chronic HF.<sup>3-6</sup> Lipid peroxides and 8-iso-prostaglandin F<sub>2α</sub>, which are the major biochemical consequences of ROS generation, have been shown to be elevated in plasma and pericardial fluid of patients with HF and also positively correlated to the severity of HF.<sup>3,4</sup> However, all of these findings have provided only indirect evidence of ROS generation in the failing hearts. It is difficult to quantify the amount of ROS in the intact biological system since they are unstable and rapidly react with unoxidized adjacent molecules and thus their half life is very short. The only method to directly quantify ROS in biological tissue is electron spin resonance (ESR) spectroscopy. Using ESR combined with the nitroxide radical, 4-hydroxy-2,2,6,6-tetramethyl-piperidine-N-oxyl (hydroxy-TEMPO), as a spin probe, we first provided a definitive and direct demonstration of enhanced generation of ROS in the failing myocardium.<sup>7</sup>  $\cdot\text{O}_2^-$  is a primary radical that could lead to the formation of other ROS, such as  $\text{H}_2\text{O}_2$  and  $\cdot\text{OH}$ , in the failing myocardium.  $\cdot\text{OH}$  could arise from electron exchange between  $\cdot\text{O}_2^-$  and  $\text{H}_2\text{O}_2$  via the Harber-Weiss reaction. In addition,  $\cdot\text{OH}$  is also generated by the reduction of  $\text{H}_2\text{O}_2$  in the presence of endogenous iron by means of the Fenton reaction. The generation of  $\cdot\text{OH}$  implies a pathophysiological significance of ROS in HF since  $\cdot\text{OH}$  radicals are the predominant oxidant species causing cellular injury.

The decreased antioxidant capacity could further aggravate the ROS accumulation in HF. However, the activities of SOD, catalase, and GSHPx were not decreased in the failing hearts.<sup>8</sup> These results thus indicate that oxidative stress in HF is primarily due to the enhancement of prooxidant generation rather than to the decline in antioxidant defenses. Moreover, the generation of ROS is greater than the scavenging capacity of endogenous antioxidants within the failing myocardium.

### *Mitochondria as an Enzymatic Source of ROS Production*

Possible cellular sources of ROS generation within the heart include cardiac myocytes, endothelial cells, and neutrophils. Within cardiac myocytes, ROS can be produced by several mechanisms including mitochondrial electron transport, NADPH oxidase, and xanthine dehydrogenase/xanthine oxidase. Mitochondria produce ROS through one electron carriers in the respiratory chain. Under physiological conditions, small quantities of ROS are formed during mitochondrial respiration, which, however, can be detoxified by the endogenous scavenging mechanisms of myocytes.

$\cdot\text{O}_2^-$  can be assessed by using ESR spectroscopy with 5,5'-dimethyl-1-pyrroline-N-oxide (DMPO) as a spin trap, a standard method to detect ROS in the biological tissue. The inhibition of electron transport at the sites of complex I and complex III in the normal submitochondrial particles results in a significant production of  $\cdot\text{O}_2^-$ .<sup>9</sup> HF mitochondria produce more  $\cdot\text{O}_2^-$  than normal mitochondria in the presence of NADH, but not succinate as a substrate, indicating that complex I is the predominant source of such  $\cdot\text{O}_2^-$  production (**Figure 1 and 2**). Furthermore, HF mitochondria are associated with a decrease in complex I activity. Therefore, mitochondria are the predominant source of ROS in failing hearts, indicating a pathophysiological link between mitochondrial dysfunction and oxidative stress<sup>10</sup> as has been reported in other disease conditions including aging and neurodegenerative diseases.

Even though mitochondrial electron transport is considered to play an important role in the ROS production in HF, we could not completely exclude the possibility that other enzymatic sources of ROS generation such as vascular endothelial cells (via xanthine oxidase and/or NADPH oxidase) and activated leukocytes (via NADPH oxidase) could contribute to oxidative stress in HF.<sup>11</sup> In fact, Bauersachs et al have demonstrated that vascular NAD(P)H oxidase is activated in HF.<sup>12</sup> This enzyme system is the major source of ROS in both the

endothelium and vascular smooth muscle. They are able to generate ROS in response to angiotensin II, which stimulates the expression of NAD(P)H oxidase. Plasma renin activity as well as tissue ACE activity is activated in HF. Therefore, an enhanced formation of angiotensin II may lead to oxidative stress via this enzyme system in HF.

### *Oxidative Stress and Mitochondrial DNA Damage*

ROS can damage mitochondrial macromolecules either at or near the site of their formation. Therefore, in addition to the role of mitochondria as a source of ROS, the mitochondria themselves can be damaged by ROS.

Mitochondria contain closed circular, double-strand DNA of ~16.5 kb. Both strands of the mitochondrial DNA (mtDNA) are transcribed. The mitochondrial genome encodes 13 polypeptides involved in oxidative phosphorylation, including 7 subunits (ND1, ND2, ND3, ND4, ND4L, ND5, and ND6) of rotenone-sensitive NADH-ubiquinone oxidoreductase (complex I), 1 subunit (cytochrome b) of ubiquinol-cytochrome c oxidoreductase (complex III), 3 subunits (COI, COII, and COIII) of cytochrome-c oxidase (complex IV), and 2 subunits (ATPases 6 and 8) of complex V along with 22 tRNAs and 2 rRNA (12S and 16S) subunits (**Figure 3**). The polypeptides are translated by mitochondrial ribosomes and consist of components of the electron transport chain.

The mtDNA could be a major target for ROS-mediated damage for several reasons. First, mitochondria do not have a complex chromatin organization consisting of histone proteins, which may serve as a protective barrier against ROS. Second, mtDNA has a limited repair activity against DNA damage. Third, a large part of  $\cdot\text{O}_2^-$  which is formed inside the mitochondria can not pass through the membranes and, hence, ROS damage may be contained largely within the mitochondria. In fact, mtDNA accumulates significantly higher levels of the DNA oxidation product, 8-hydroxydeoxyguanosine, than nuclear DNA.<sup>13</sup> As opposed to nuclear-encoded genes, mitochondrial-encoded gene expression is

largely regulated by the copy number of mtDNA.<sup>14</sup> Therefore, mitochondrial injury is reflected by mtDNA damage as well as by a decline in the mitochondrial RNA (mtRNA) transcripts, protein synthesis, and mitochondrial function.<sup>15,16</sup> We have recently shown that the increased generation of ROS was associated with mitochondrial damage and a dysfunction in the failing hearts, which were characterized by an increased lipid peroxidation in the mitochondria, a decreased mtDNA copy number, a decrease in the number of mtRNA transcripts, and a reduced oxidative capacity due to low complex enzyme activities.<sup>17</sup> Chronic increases in ROS production are associated with mitochondrial damage and dysfunction which thus can lead to a catastrophic cycle of mitochondrial functional decline, further ROS generation, and cellular injury (**Figure 4**). MtDNA defects may thus play an important role in the development and progression of myocardial remodeling and failure.

Several possible factors might be involved as the stimuli for increased ROS in HF. The activation of neurohumoral factors commonly seen in HF, including catecholamines and cardiac sympathetic tone, renin-angiotensin system, cytokines, and nitric oxide (NO), can all contribute to the generation of ROS. If mitochondria are the principle source of ROS in response to cytokines such as TNF $\alpha$  and NO, such stimuli may directly modify mitochondrial electron transport function and lead to  $\cdot\text{O}_2^-$  production. Generation of ROS, mtDNA decline, and loss of complex activity could be observed also in vitro when cardiac myocytes were exposed to TNF $\alpha$ .<sup>18</sup> The equivalent results observed between in vivo and in vitro indicate that TNF $\alpha$  plays an important role in oxidative stress in the pathogenesis of myocardial remodeling and failure. Further, overexpression of TNF $\alpha$  gene induced the increase in ROS production in association with the myocardial contractile dysfunction and structural remodeling in mice.<sup>19</sup>

A number of pathogenic mtDNA base substitution mutations, such as missense mutations and mtDNA rearrangement mutations (deletions and insertions), have been identified in patients with mitochondrial diseases.<sup>20</sup> An



accumulation of the deleted forms of mtDNA in the myocardium frequently results in either cardiac hypertrophy, conduction block, or HF.<sup>21</sup> Furthermore, there is now a consensus view that mutations in mtDNA and abnormalities in mitochondrial function are associated with common forms of cardiac diseases such as ischemic heart disease<sup>22</sup> and dilated cardiomyopathy.<sup>23</sup> In these conditions, however, the strict causal relationships between abnormalities in mtDNA and cardiac dysfunction have yet to be fully elucidated.<sup>24</sup> Even though the mechanisms by which mtDNA damage arises in these conditions have not been clarified, ROS have been proposed to be the primary contributing factor. We have provided direct evidence that mtDNA defects occur not only in a limited small subset of mitochondrial diseases but also in a more common HF phenotype occurring after myocardial infarction (MI). This is further supported by the studies on mice lacking MnSOD which show an accumulation of oxidative damage of mtDNA and electron transport complexes<sup>25</sup> in association with the development of dilated cardiomyopathy.<sup>26</sup>

ROS can cause an oxidative modification of nucleotides, such as 8-oxo-7,8-dihydrodeoxyguanosine triphosphate (8-oxo-dGTP), which can lead to defects in DNA replication. The misincorporation of 8-oxo-dGTP into DNA is prevented by 8-oxo-dGTPase, which hydrolyzes 8-oxo-dGTP into 8-oxo-dGMP. We have demonstrated that 8-oxo-dGTPase was highly expressed in the cardiac myocytes from the post-MI failing hearts, thus suggesting that this enzymatic system preventing oxidative DNA damage may be activated in response to increased oxidative stress.<sup>27</sup>

### *Oxidative Stress and Myocardial Damage*

ROS have direct effects on cellular structure and function and may be integral signaling molecules in myocardial remodeling and failure. ROS result in a phenotype characterized by hypertrophy and apoptosis in isolated cardiac myocytes.<sup>28</sup> ROS have also been shown to activate matrix metalloproteinase

(MMP) in cardiac fibroblasts.<sup>29</sup> Myocardial MMP activity is increased in the failing hearts.<sup>30,31</sup> Further, an MMP inhibitor has been shown to limit early LV dilatation in a murine model of MI.<sup>32</sup> We have shown the significant improvement in the survival after MI in MMP-2 knockout mice, which was mainly attributable to the inhibition of early cardiac rupture and the development of a subsequent LV dysfunction.<sup>33</sup> Because MMP can be activated by ROS,<sup>34</sup> one proposed mechanism of LV remodeling is the activation of MMPs secondary to increased ROS production. Sustained MMP activation might therefore influence the structural properties of the myocardium by providing an abnormal extracellular environment with which the myocytes interact. We have demonstrated that ·OH scavenger, dimethylthiourea, inhibits the activation of MMP-2 in association with the development of LV remodeling and failure.<sup>35</sup> These data raise the interesting possibility that increased ROS after MI can be a stimulus for myocardial MMP activation, which might play an important role in the development of HF.

An HMG-CoA reductase inhibitor, fluvastatin, inhibits the production of MMPs at a concentration as low as 5 µmol/L in vitro.<sup>36</sup> Chronic administration of statin into post-MI mice can improve the survival and inhibit the development of cardiac remodeling and failure.<sup>37</sup> These effects were associated with the attenuation of an increase of myocardial MMPs, MMP-2 and MMP-13, in the noninfarcted LV, the site of ongoing remodeling, which was significantly attenuated in fluvastatin-treated animals.<sup>37</sup>

### *Oxidative Stress and Skeletal Muscle Dysfunction*

Oxidative stress could be the mechanistic basis also for muscle fatigue and reduced exercise tolerance in HF patients.<sup>38</sup> This notion is supported by a positive correlation between ROS and exercise intolerance in these patients.<sup>39</sup> Further, we demonstrated that the production of ROS was increased in the skeletal muscle homogenates obtained from a murine model of HF and increased ROS were

identified as  $\cdot\text{OH}$  originating from  $\cdot\text{O}_2^-$ , which was associated with a concomitant increase in the oxidation of lipids.<sup>40</sup> These results are consistent with the previous studies that the oxidative capacity is reduced and  $\text{O}_2$  utilization is inadequate in skeletal muscle mitochondria from HF patients.<sup>41</sup> Skeletal muscle mitochondria from HF are associated with a decrease in the activities of complex I and complex III.<sup>40</sup> As has been shown in the failing hearts,<sup>9</sup> the defects in electron transfer function may lead to the ROS production. ROS may play an important role in the muscle atrophy commonly seen in HF patients through the induction of apoptosis. In addition, ROS impair myoplasmic  $\text{Ca}^{2+}$  homeostasis and inhibit the oxidative energy production in the mitochondria, both of which may contribute to the muscle contractile dysfunction. An attempt to attenuate oxidative stress would improve, to some extent, the exercise capacity of patients with HF.

### **Novel Therapeutic Strategies of HF Targeting Oxidative Stress**

Oxidative stress is now proved to play an important role in the development and progression of myocardial remodeling and failure. Based on this novel paradigm, we expect that novel therapeutic strategies of HF could be developed. A growing body of evidence suggests that antioxidants exert protective and beneficial effects in experimental HF.<sup>35,42-45</sup> An antioxidant vitamin E prevented the transition from hypertrophy to failure in the guinea pig model of ascending aortic constriction.<sup>43</sup> In addition, probucol, lipid-lowering as well as potent antioxidant agent, had protective effects against pacing-induced HF<sup>44</sup> and adriamycin-induced cardiomyopathy.<sup>45</sup>

The first line of defense mechanism against ROS-mediated cardiac injury comprises several antioxidant enzymes including SOD, catalase, and GSHPx. Among these antioxidants, GSHPx is an important enzyme that performs several vital functions. GSHPx is a key antioxidant which catalyses the reduction of  $\text{H}_2\text{O}_2$  and hydroperoxides. It not only scavenges  $\text{H}_2\text{O}_2$  but also prevents the formation of other more toxic radicals such as  $\cdot\text{OH}$ . GSHPx possesses a higher affinity for

H<sub>2</sub>O<sub>2</sub> than catalase. Further, it is present in relatively high amounts within the heart especially in the cytosolic and mitochondrial compartments.<sup>46</sup> These lines of evidence imply the primary importance of GSHPx as a defense mechanism within the heart compared to catalase. Moreover, GSHPx is expected to exert greater protective effects against oxidative damage than SOD because greater dismutation of ·O<sub>2</sub><sup>-</sup> by SOD may result in an increase of H<sub>2</sub>O<sub>2</sub>. Therefore, compared with SOD or catalase, GSHPx is thought to be more effective in protecting cells, tissues, and organs against oxidative damage.<sup>47</sup> We have recently demonstrated that GSHPx overexpression inhibited the development of LV remodeling and failure after MI (**Figure 5 and 6**), which might contribute to the improved survival.<sup>48</sup> These findings not only extended the previous observation that employed antioxidants, but also revealed the major role of ROS in the pathophysiology of post-MI remodeling. These effects were associated with the attenuation of myocyte hypertrophy, apoptosis, and interstitial fibrosis.<sup>48</sup> Further, peroxiredoxin (Prx )-3, one of 6 distinct Prx family members identified in mammals which can scavenge H<sub>2</sub>O<sub>2</sub>, may also exert protective effects against myocardial oxidative damage because it is specifically located in the mitochondria.<sup>49</sup>

Oxidative stress is involved not only in HF, but also in various cardiovascular diseases including atherosclerosis and hypertension. Therefore, therapeutic strategies to modulate this maladaptive response should definitely become a target for future extensive investigation and therapies designed to interfere with oxidative stress, especially within the mitochondria, could have a broader application.

## **Clinical Approach**

### **Management of the “Real World” Patients with HF**

The clinical characteristics, drug therapy, and prognosis of patients with HF have been well described by a number of both community-based<sup>50-53</sup> and hospital-based studies,<sup>54-56</sup> as well as by clinical trials of HF treatment.<sup>57-60</sup> However, these studies have been performed mainly in the United States and Europe and very little information is available in Japan. The previous results may not be directly translatable from one country to another which has different population with different health care system since variations in the population and quality of care may be important cofactors in the interactions among disease severity and outcome.<sup>61</sup> Furthermore, race is an important determinant of certain clinical outcomes in cardiovascular diseases.<sup>62,63</sup>

### **The “Real World” Patients with HF**

We assessed the characteristics of patients consecutively hospitalized and discharged with HF during 1997 and the status of these patients was followed through December 1999. The study institutions included 5 cardiology units (1 university hospital and 4 nearby hospitals) serving as primary, secondary, and tertiary referral medical centers for cardiovascular patients in Fukuoka with 1.3 million inhabitants.<sup>64</sup>

#### *Age Distribution*

The mean age was 69±14 years (range 16 to 92), and 70% of patients were >65 years of age. Overall, 60% were men and 40% women. The number of patients with HF increased with advancing age (**Figure 7**). Especially, women were found mostly in older than 70 years.

#### *Causes of HF*

Among HF patients, ischemic heart disease was the dominant cause and was involved in one thirds of the cases (**Figure 8**). This value is comparable to that reported in recent studies in Europe, but is lower than those in the clinical

trials that large proportion of patients (60-75%) was attributed to ischemic cause<sup>65</sup> Another unique feature is that hypertensive heart disease was found in 20%. This figure is comparable to that observed in the study in Sweden (17%)<sup>55</sup> and that in Italy (15%),<sup>54</sup> but lower than that recognized in the population-based studies. Hypertension is still an important causative and contributing factor for HF and the importance of its treatment has been also supported by the recent evidence that the effective antihypertensive therapy can reduce the incidence of HF.<sup>57,66</sup>

#### *HF with Preserved Systolic Function*

The high proportion of patients had relatively preserved LV systolic function.<sup>67</sup> The half of patients with definite HF who had echocardiography had normal ejection fraction (>50 %), indicating the contribution of diastolic dysfunction in the pathogenesis of HF.<sup>68</sup> Patients with preserved systolic function were more often women and had a higher prevalence of cardiac hypertrophy. At follow-up, cumulative survival probabilities were similar between patients with preserved systolic function and those with systolic dysfunction. Further, readmission rates were also comparable between preserved and depressed systolic function. In light of these findings, effective therapeutic strategy for this subset of patients needs to be established.

#### *Prognosis*

Our patient population hospitalized with HF had a relatively good survival prognosis; the 1-year mortality rate being 8.3 % (**Figure 9**).<sup>64</sup> In contrast to the relatively low mortality, rates of readmission for HF were as high as 40%. This value was comparable to those in prior studies (a 3- to 6-month readmission rate 30 to 50 %).<sup>69-71</sup> The most commonly identified cause for hospital readmission was lack of compliance with medical and dietary treatment.<sup>72</sup> Further studies to identify the independent factors contributing for the hospital readmission have

demonstrated that patients with a previous history of hospitalization due to HF, longer hospital stay, and a history of hypertension are at increased risk for readmission, and that socioeconomic factors, including poor follow-up visits, poor professional support, and no occupation, are also potentially important predictors of HF-related readmission.<sup>72</sup>

### **The Nationwide Survey of HF Patients in Japan**

Even though our previous studies have provided a valuable insight into the effective treatment strategies for HF patients,<sup>64,67,72</sup> the generality of our results is questioned because our investigation was conducted in a small number of patients. Furthermore, the participating hospitals are not representative of all cardiology units in the geographic area. However, the aim of our previous preliminary studies are to obtain a realistic picture of the characteristics of patients with HF admitted to the hospital cardiology units rather than a precise evaluation of the prevalence of HF as an epidemiological study.

It is of critical importance to analyze the realistic data of HF patients on a nationwide basis, and to form a database for future investigations. For this purpose, a nationwide survey is now started by the Japanese Cardiac Registry (JCARE) investigators with the support of the Japanese Circulation Society and the Japanese Society of Heart Failure. One survey focused on the demographic and clinical characteristics, treatment strategies, and long-term outcomes in patients admitted to the nationwide hospitals in Japan due to the worsening of HF symptoms during 2004 (JCARE-CARD; **Figure 10**). The other survey evaluated the demographic and clinical characteristics, treatment drugs, and long-term outcomes in patients with HF treated at the outpatient settings (JCARE-GENERAL; **Figure 11**). The primary goal of JCARE study is 1) to characterize the nationwide contemporary features of HF patients and 2) to delineate the independent predictors of prognosis in the “real world” patients with HF in Japan.

## **Effective Strategies of Treatment and Management for HF**

There is an urgent need to develop and establish more effective strategies to prevent the progression and exacerbation of HF. Based on the findings obtained from our preliminary survey of the “real world” patients with HF, systematic patient management that coordinates care in the hospital, outpatient, and home settings is expected to reduce the morbidity of these patients. It is also important to employ interventions that can prevent readmission especially for high-risk patients.

## **Conclusions**

Both basic and clinical approaches are needed to improve the prognosis of patients with HF. First is the further development of novel therapeutic strategies based on a novel insight into the pathophysiology of myocardial remodeling and failure. Our approach is to develop the therapeutic strategy of myocardial remodeling by regulating mitochondrial oxidative stress. Second is the improvement of quality of care in routine clinical practice. These approaches need to be continued to establish the novel and most effective treatment strategies for Japanese patients with HF.



## **Acknowledgments**

I am grateful to Dr. Akira Takeshita and coworkers, Drs. Yuji Ishibashi, Takashi Namba, Masaru Takahashi, Keiko Igarashi-Saito, Shimako Yamamoto-Nagasawa, Tomomi Ide, Miyuki Tsuchihashi, Shintaro Kinugawa, Shunji Hayashidani, Nobuhiro Suematsu, Tetsuya Shiomi, Masaki Ikeuchi, Hidenori Matsusaka, Shouji Matsushima, Jing Wen, Toru Kubota, Kensuke Egashira in the Department of Cardiovascular Medicine, Kyushu University for their extensive contribution to our studies. I also thank Drs. Kimiyo Murakami, Kazuo Ichikawa, and Hideo Utsumi (Department of Biophysics, Graduate School of Pharmaceutical Sciences, Kyushu University), Drs. Dongchon Kang and Naotaka Hamasaki (Department of Clinical Chemistry and Laboratory Medicine, Kyushu University), and Dr. Kei-ichiro Nakamura (Department of Developmental Molecular Anatomy, Kyushu University) for their collaboration. Participating investigators constituting the HF patients in Fukuoka are as follows; Samon Koyanagi, MD (National Kyushu Medical Center Hospital); Tetsuji Inou, MD and Masami Matsuyama, RN (Fukuoka Red Cross Hospital); Yuji Maruoka, MD (Hamanomachi Hospital); Yusuke Yamanoto, MD (Saiseikai Fukuoka General Hospital). This study could not have been carried out without help, cooperation, and support of the cardiologists in the study hospitals. I express sincere thanks to Drs. Motoomi Nakamura, Hitonobu Tomoike (National Cardiovascular Center), and Kenji Sunagawa (Kyushu University) for their valuable support to our work.

The work presented in this article was supported in part by grants from the Ministry of Education, Science and Culture, Japan (No. 07266220, 08258221, 09670724, 12670676, 14370230), Health Sciences Research Grants (Research on Health Services) from the Japanese the Ministry of Health, Labour and Welfare (#10150305), and Japan Arteriosclerosis Prevention Fund.

## References

1. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. *J Am Coll Cardiol* 1993;**22**:6A-13A.
2. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. *N Engl J Med* 1985;**312**:159-163.
3. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. *Br Heart J* 1991;**65**:245-248.
4. Mallat Z, Philip I, Lebreton M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F<sub>2</sub>alpha in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. *Circulation* 1998;**97**:1536-1539.
5. Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. *Am J Pathol* 1996;**148**:291-300.
6. Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. *Circulation* 1997;**96**:2414-2420.
7. Ide T, Tsutsui H, Kinugawa S, Suematsu N, Hayashidani S, Ichikawa K, et al. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. *Circ Res* 2000;**86**:152-157.
8. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Utsumi H, Nakamura R, et al. Greater susceptibility of failing cardiac myocytes to oxygen free radical-mediated injury. *Cardiovasc Res* 2001;**49**:103-109.
9. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. *Circ Res* 1999;**85**:357-363.
10. Sawyer DB, Colucci WS. Mitochondrial oxidative stress in heart failure: "oxygen wastage" revisited. *Circ Res* 2000;**86**:119-120.

11. Munzel T, Harrison DG. Increased superoxide in heart failure: a biochemical baroreflex gone awry. *Circulation* 1999;**100**:216-218.
12. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. *Circulation* 1999;**100**:292-298.
13. Giulivi C, Boveris A, Cadenas E. Hydroxyl radical generation during mitochondrial electron transfer and the formation of 8-hydroxydesoxyguanosine in mitochondrial DNA. *Arch Biochem Biophys* 1995;**316**:909-916.
14. Williams RS. Mitochondrial gene expression in mammalian striated muscle. Evidence that variation in gene dosage is the major regulatory event. *J Biol Chem* 1986;**261**:12390-12394.
15. Williams RS. Canaries in the coal mine: mitochondrial DNA and vascular injury from reactive oxygen species. *Circ Res* 2000;**86**:915-916.
16. Ballinger SW, Patterson C, Yan CN, Doan R, Burow DL, Young CG, et al. Hydrogen peroxide- and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. *Circ Res* 2000;**86**:960-966.
17. Ide T, Tsutsui H, Hayashidani S, Kang D, Suematsu N, Nakamura K, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. *Circ Res* 2001;**88**:529-535.
18. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. *Circulation* 2003;**107**:1418-1423.

19. Machida Y, Kubota T, Kawamura N, Funakoshi H, Ide T, Utsumi H, et al. Overexpression of tumor necrosis factor- $\alpha$  increases production of hydroxyl radical in murine myocardium. *Am J Physiol Heart Circ Physiol* 2003;**284**:H449-455.
20. Wallace DC. Mitochondrial diseases in man and mouse. *Science* 1999;**283**:1482-1488.
21. Anan R, Nakagawa M, Miyata M, Higuchi I, Nakao S, Suehara M, et al. Cardiac involvement in mitochondrial diseases. A study on 17 patients with documented mitochondrial DNA defects. *Circulation* 1995;**91**:955-961.
22. Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. *Mutat Res* 1992;**275**:169-180.
23. Arbustini E, Diegoli M, Fasani R, Grasso M, Morbini P, Banchieri N, et al. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. *Am J Pathol* 1998;**153**:1501-1510.
24. Clayton DA, Williams RS, Liang IY. Meeting Highlights. *Circulation* 1995;**92**:2022-2023.
25. Williams MD, Van Remmen H, Conrad CC, Huang TT, Epstein CJ, Richardson A. Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. *J Biol Chem* 1998;**273**:28510-28515.
26. Melov S, Schneider JA, Day BJ, Hinerfeld D, Coskun P, Mirra SS, et al. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. *Nat Genet* 1998;**18**:159-163.
27. Tsutsui H, Ide T, Shiomi T, Kang D, Hayashidani S, Suematsu N, et al. 8-oxo-dGTPase, which prevents oxidative stress-induced DNA damage, increases in the mitochondria from failing hearts. *Circulation* 2001;**104**:2883-2885.

28. Siwik DA, Tzortzis JD, Pimental DR, Chang DL, Pagano PJ, Singh K, et al. Inhibition of copper-zinc superoxide dismutase induces cell growth, hypertrophic phenotype, and apoptosis in neonatal rat cardiac myocytes in vitro. *Circ Res* 1999;**85**:147-153.
29. Siwik DA, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. *Am J Physiol Cell Physiol* 2001;**280**:C53-60.
30. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? *Circ Res* 2001;**89**:201-210.
31. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. *Circ Res* 1998;**82**:482-495.
32. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. *Circulation* 1999;**99**:3063-3070.
33. Hayashidani S, Tsutsui H, Ikeuchi M, Shiomi T, Matsusaka H, Kubota T, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. *Am J Physiol Heart Circ Physiol* 2003;**285**:H1229-1235.
34. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. *J Clin Invest* 1996;**98**:2572-2579.
35. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and

- failure after experimental myocardial infarction in mice: role of oxidative stress. *Circ Res* 2000;**87**:392-398.
36. Ikeda U, Shimpo M, Ohki R, Inaba H, Takahashi M, Yamamoto K, et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. *Hypertension* 2000;**36**:325-329.
37. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. *Circulation* 2002;**105**:868-873.
38. Wilson JR. Exercise intolerance in heart failure. Importance of skeletal muscle. *Circulation* 1995;**91**:559-561.
39. Nishiyama Y, Ikeda H, Haramaki N, Yoshida N, Imaizumi T. Oxidative stress is related to exercise intolerance in patients with heart failure. *Am Heart J* 1998;**135**:115-120.
40. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Shiomi T, Wen J, et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. *Circulation* 2001;**104**:134-136.
41. Mancini DM, Coyle E, Coggan A, Beltz J, Ferraro N, Montain S, et al. Contribution of intrinsic skeletal muscle changes to <sup>31</sup>P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. *Circulation* 1989;**80**:1338-1346.
42. Sia YT, Lapointe N, Parker TG, Tsoporis JN, Deschepper CF, Calderone A, et al. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. *Circulation* 2002;**105**:2549-2555.
43. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. *J Am Coll Cardiol* 1996;**28**:506-514.
44. Nakamura R, Egashira K, Machida Y, Hayashidani S, Takeya M, Utsumi H, et al. Probucol attenuates left ventricular dysfunction and remodeling in

- tachycardia-induced heart failure: roles of oxidative stress and inflammation. *Circulation* 2002;**106**:362-367.
45. Siveski-Iliskovic N, Hill M, Chow DA, Singal PK. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. *Circulation* 1995;**91**:10-15.
  46. Le CT, Hollaar L, van der Valk EJ, van der Laarse A. Buthionine sulfoximine reduces the protective capacity of myocytes to withstand peroxide-derived free radical attack. *J Mol Cell Cardiol* 1993;**25**:519-528.
  47. Toussaint O, Houbion A, Remacle J. Relationship between the critical level of oxidative stresses and the glutathione peroxidase activity. *Toxicology* 1993;**81**:89-101.
  48. Shiomi T, Tsutsui H, Matsusaka H, Murakami K, Hayashidani S, Ikeuchi M, et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. *Circulation* 2004;**109**:544-549.
  49. Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. *J Biol Chem* 1998;**273**:6297-6302.
  50. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. *Circulation* 1993;**88**:107-115.
  51. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. *N Engl J Med* 1971;**285**:1441-1446.
  52. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. *J Am Coll Cardiol* 1992;**20**:301-306.

53. Rodeheffer RJ, Jacobsen SJ, Gersh BJ, Kottke TE, McCann HA, Bailey KR, et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. *Mayo Clin Proc* 1993;**68**:1143-1150.
54. SEOSI Investigators. Survey on heart failure in Italian hospital cardiology units. Results of the SEOSI study. *Eur Heart J* 1997;**18**:1457-1464.
55. Andersson B, Waagstein F. Spectrum and outcome of congestive heart failure in a hospitalized population. *Am Heart J* 1993;**126**:632-640.
56. The Myocardopathy and Heart Failure Working Group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society. Cohen-Solal A, Desnos M, Delahaye F, Emeriau JP, Hanania G. A national survey of heart failure in French hospitals. *Eur Heart J* 2000;**21**:763-769.
57. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991;**265**:3255-3264.
58. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med* 1991;**325**:303-310.
59. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. *N Engl J Med* 1986;**314**:1547-1552.
60. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med* 1987;**316**:1429-1435.



61. Kahn KL, Pearson ML, Harrison ER, Desmond KA, Rogers WH, Rubenstein LV, et al. Health care for black and poor hospitalized Medicare patients. *JAMA* 1994;**271**:1169-1174.
62. Gibbs CR, Lip GY. Ethnicity and heart failure. *Eur Heart J* 1999;**20**:1436-1437.
63. Gillum RF. The epidemiology of cardiovascular disease in black Americans. *N Engl J Med* 1996;**335**:1597-1599.
64. Tsuchihashi M, Tsutsui H, Kodama K, Kasagi F, Takeshita A. Clinical characteristics and prognosis of hospitalized patients with congestive heart failure--a study in Fukuoka, Japan. *Jpn Circ J* 2000;**64**:953-959.
65. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. *Circulation* 1998;**97**:282-289.
66. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet* 1991;**338**:1281-1285.
67. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. *Am J Cardiol* 2001;**88**:530-533.
68. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. *J Am Coll Cardiol* 1999;**33**:1948-1955.
69. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. *J Am Geriatr Soc* 1990;**38**:1290-1295.
70. Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford MJ, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. *Arch Intern Med* 1997;**157**:99-104.

71. Chin MH, Goldman L. Correlates of early hospital readmission or death in patients with congestive heart failure. *Am J Cardiol* 1997;**79**:1640-1644.
72. Tsuchihashi M, Tsutsui H, Kodama K, Kasagi F, Setoguchi S, Mohr M, et al. Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure. *Am Heart J* 2001;**142**:E7.

## Figure legends

**Figure 1** Components of the respiratory chain in mitochondria. FAD, flavin adenine nucleotide; FMN, flavin mononucleotide; Fe-S, iron-sulfur protein; Q, ubiquinone, Cyt, cytochrome. (Reproduced with permission from Ide T et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium *Circ Res* 85:357-363,1999)

**Figure 2** An ESR analysis of 5,5'-dimethyl-1-pyrroline-*N*-oxide (DMPO) adduct formation in HF mitochondria in the presence of NADH (A) and succinate (B). (A) The reaction mixture consisted of submitochondrial particles obtained from the HF heart (2 mg protein/ml), NADH (200  $\mu\text{mol/L}$ ) with alcohol dehydrogenase (9 U/mL) to regenerate NADH or succinate (10 mmol/L), and DMPO in phosphate buffered saline, pH 7.4. Note that the DMPO-OOH signals were amplified in the presence of antimycin A (200  $\mu\text{mol/L}$ ), but not in the presence of rotenone (200  $\mu\text{mol/L}$ ). (B) Similar to NADH, when succinate was reacted with the mitochondria, the DMPO-OOH signals were enhanced in the presence of antimycin A. Instrumental conditions; X-band (9.43 GHz) ESR; microwave power 10 mW; field modulation width 0.063 mT; sweep time 5 mT/min. (Reproduced with permission from Ide T et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium *Circ Res* 85:357-363,1999)

**Figure 3** Map of the mitochondrial genome. The 16.3-kilobase mouse mitochondrial genome is diagrammed showing the 13 mRNA, 2 rRNA (12S and 16S), and 21 tRNA coding genes. mRNA genes are shown as the areas labeled with the codes of the corresponding electron transport chain complexes I, III, IV, and V. PH and PL refer to the promoters of heavy (H) and light (L) strand transcription, respectively. (Reproduced with permission from Ide T et al.

Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts following MI. *Circ Res* 88:529-535,2001)

**Figure 4** Schematic representation of an intimate link between ROS, mtDNA damage, and respiratory chain dysfunction in the mitochondria. Mitochondrial ROS generation may lead to a catastrophic cycle of mitochondrial functional decline, further ROS generation, and cellular injury. (Reproduced with permission from Ide T et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts following MI. *Circ Res* 88:529-535,2001)

**Figure 5** M-mode echocardiograms obtained from wild-type mice (WT)+Sham (A), GSHPx transgenic mice (TG)+Sham (B), WT+MI (C), and TG+MI (D) mice. AW, anterior wall. PW, posterior wall. EDD, end-diastolic diameter. (Reproduced with permission from Shiomi T et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. *Circulation* 109:544-549,2004)

**Figure 6** Low-power photomicrographs of Masson-trichrome-stained LV cross-section obtained from WT+MI (A) and TG+MI (B) mice. Scale bar, 1 mm. (Reproduced with permission from Shiomi T et al. Overexpression of glutathione peroxidase prevents left ventricular remodeling and failure after myocardial infarction in mice. *Circulation* 109:544-549,2004)

**Figure 7** Age distribution of men (open bars) and women (closed bars) hospitalized with congestive heart failure. (Tsuchihashi M et al. Clinical characteristics and prognosis of consecutively hospitalized patients with congestive heart failure: A study in Fukuoka, Japan. *Jpn Circ J* 64:953-959, 2000)

**Figure 8** Distribution of causes of heart failure. Patients could have more than one cause. Numbers denote the percentage of patients to the total number of study patients. (Tsuchihashi M et al. Clinical characteristics and prognosis of consecutively hospitalized patients with congestive heart failure: A study in Fukuoka, Japan. *Jpn Circ J* 64:953-959, 2000)

**Figure 9** Cumulative rate of readmission, cardiac death, and noncardiac death in all patients with heart failure after discharge. (Tsuchihashi M et al. Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure. *Am Heart J* 142:e7,2001)

**Figure 10** JCARE-CARD (<http://www.jcare-card.jp/>). Homepage images for the patient registration.

**Figure 11** JCARE-GENERAL. The nationwide location of study areas in Japan.



# JCARE

-CARD

## Japanese CARDiac REGistry in CHF-CARDiology

慢性心不全の増悪のため  
入院治療を要する患者を対象とした調査研究



# JCARE-GENERAL

n=2594 patients

